Literature DB >> 19463314

Renal frame count and renal blush grade: quantitative measures that predict the success of renal stenting in hypertensive patients with renal artery stenosis.

Ehtisham Mahmud1, Thomas W R Smith, Vachaspathi Palakodeti, Owais Zaidi, Lawrence Ang, C Robinson Mitchell, Nayab Zafar, Guilherme Bromberg-Marin, Shahin Keramati, Sotirios Tsimikas.   

Abstract

OBJECTIVES: This study sought to identify angiographic parameters of favorable clinical response to renal artery stenting.
BACKGROUND: Stenting improves blood pressure (BP) control in patients with renal artery stenosis (RAS), but markers predicting a favorable clinical response are limited.
METHODS: Renal perfusion was quantified in hypertensive patients (BP >or=140/90 mm Hg) without RAS by determining renal frame count (RFC) (angiographic frames [30 frames/s] for contrast to reach distal renal parenchyma after initial renal artery opacification) and renal blush grade (RBG) (0: none, 1: minimal, 2: normal, 3: hyperemic parenchymal blush). It was hypothesized that stenting unilateral RAS in hypertensive patients would result in decreased RFC and increased RBG, which might predict BP reduction.
RESULTS: The RFC in 17 consecutive hypertensive patients without RAS (control group) (64.4 +/- 14.2 years, 12 male, 22 kidneys) was 20.1 +/- 5.4, whereas RBG was 2.33 +/- 0.66. In 24 consecutive hypertensive patients with unilateral RAS (study group) (72.7 +/- 11.3 years, 8 male), reduced RFC (26.6 +/- 9.1 to 21.4 +/- 6.7, p < 0.001) and increased RBG (1.63 +/- 0.71 to 2.13 +/- 0.85, p = 0.03) were observed after renal stenting. At 6 months, reduced BP (systolic BP 150.6 +/- 15.6 mm Hg to 128.6 +/- 15.5 mm Hg, p < 0.001; diastolic BP 77.2 +/- 15.6 mm Hg to 68.3 +/- 10.4 mm Hg, p = 0.022) without change in number of hypertensive medications was observed. Clinical responders (systolic BP reduction >15 mm Hg) had a greater decrease in RFC (7.7 +/- 4.6 vs. 1.7 +/- 5.1, p = 0.009) and 78.6% of patients with >4 RFC decrease were responders (p = 0.024).
CONCLUSIONS: This study shows that quantitative indices of renal perfusion (RFC and RBG) are impaired in patients with RAS and improve after stenting, and that RFC reduction is associated with BP reduction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19463314     DOI: 10.1016/j.jcin.2008.03.012

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  6 in total

1.  Renal intervention to treat hypertension.

Authors:  Rajan A G Patel; Christopher J White
Journal:  Curr Cardiol Rep       Date:  2012-04       Impact factor: 2.931

2.  Severely Impaired Renal Function in Unilateral Atherosclerotic Renal Artery Stenosis Indicated by Renal Slow Perfusion.

Authors:  Hu Ai; Hui-Ping Zhang; Guo-Jian Yang; Nai-Xin Zheng; Guo-Dong Tang; Hui Li; Qi Zhou; Jun-Hong Ren; Ying Zhao; Fu-Cheng Sun
Journal:  Int J Gen Med       Date:  2020-10-14

3.  Impact of renal artery stent implantation on hypertension in patients with hemodialysis.

Authors:  Hiroyuki Hikita; Keisuke Kojima; Shigeki Kimura; Atsushi Takahashi; Mitsuaki Isobe
Journal:  Int J Angiol       Date:  2014-06

4.  Plasma Renin Activity Predicts the Improvement in Resistant Hypertension after Percutaneous Transluminal Renal Artery Angioplasty.

Authors:  Hyuma Daidoji; Yoshiaki Tamada; Saya Suzuki; Ken Watanabe; Taku Shikama; Yoku Kikuchi; Shigehiko Kato; Katsuaki Takahashi; Akio Fukui; Motoyuki Matsui; Tomoyasu Yahagi; Toshikazu Goto
Journal:  Intern Med       Date:  2016-12-01       Impact factor: 1.271

5.  Correlation of renal cortical blood perfusion and BP response after renal artery stenting.

Authors:  Siyu Wang; Sijie Zhang; Yan Li; Na Ma; Mengpu Li; Hu Ai; Hui Zhu; Junhong Ren; Yongjun Li; Peng Li
Journal:  Front Cardiovasc Med       Date:  2022-10-03

6.  Distal embolic protection during renal artery stenting: impact on hypertensive patients with renal dysfunction.

Authors:  Gregory M Singer; John F Setaro; Jeptha P Curtis; Michael S Remetz
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-11       Impact factor: 3.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.